Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
FendX Technologies Inc. announces the renewal of its investor relations services agreement with IR Labs Inc., involving a monthly fee of $11,500. The services include PR/media, social media, and stakeholder relations for a period of twelve months.
FendX Technologies Inc. annuncia il rinnovo del suo contratto di servizi di relazioni con gli investitori con IR Labs Inc., prevedendo un canone mensile di 11.500 dollari. I servizi includono relazioni con i media/PR, social media e relazioni con gli stakeholder per un periodo di dodici mesi.
FendX Technologies Inc. anuncia la renovación de su acuerdo de servicios de relaciones con inversores con IR Labs Inc., con una tarifa mensual de $11,500. Los servicios incluyen relaciones con medios/PR, redes sociales y relaciones con los stakeholders durante un período de doce meses.
FendX Technologies Inc.는 IR Labs Inc.와의 투자자 관계 서비스 계약을 갱신한다고 발표했습니다. 이 계약은 월 11,500달러의 수수료가 포함되며, 서비스에는 PR/미디어, 소셜 미디어 및 이해관계자 관계 관리가 12개월 동안 제공됩니다.
FendX Technologies Inc. annonce le renouvellement de son accord de services de relations avec les investisseurs avec IR Labs Inc., impliquant un frais mensuel de 11 500 dollars. Les services incluent les relations avec les médias/PR, les médias sociaux et les relations avec les parties prenantes pour une période de douze mois.
FendX Technologies Inc. gibt die Erneuerung des Dienstleistungsvertrages für Investorenbeziehungen mit IR Labs Inc. bekannt, der eine monatliche Gebühr von 11.500 Dollar beinhaltet. Die Dienstleistungen umfassen PR/Medienarbeit, Social Media und Stakeholder-Beziehungen für einen Zeitraum von zwölf Monaten.
Oakville, Ontario–(Newsfile Corp. – April 19, 2024) – FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX“) a nanotechnology company developing surface protection coatings, announces it has renewed its investor relations services agreement with IR Labs Inc. (“IR Labs“).
Pursuant to the agreement with IR Labs dated April 18, 2024, IR Labs has agreed to provide investor relations and communications services to the Company in exchange for monthly fee of $11,500. The services include development and management of PR/media, social media and stakeholder relations. The term of the IR Labs agreement is for a period of twelve months ending April 17, 2025, subject to a 30 day early termination provision. IR Labs and its principals are arm’s length to the Company. IR Labs contact information is as follows: 2-21102 76 Avenue, Langley BC V2Y 4K7, attention: Alyssa Barry, email alyssa@irlabs.ca, telephone: 604-997-0965.
About FendX Technologies Inc.
FendX is a Canada-based nanotechnology company focused on developing products to make people’s lives safer by reducing the spread of pathogens. The Company is developing both film and spray products to protect surfaces from contamination. The lead product under development, REPELWRAP™ film, is a protective surface coating film that, due to its repelling properties, prevents the adhesion of pathogens and reduces their transmission on surfaces prone to contamination. The spray nanotechnology is a bifunctional spray coating being developed to reduce contamination on surfaces by repelling and killing pathogens. The Company is conducting research and development activities using its nanotechnology in collaboration with industry-leading partners, including McMaster University. The Company has exclusive worldwide licenses to its technology and IP portfolio from McMaster, which encompass both film and spray coating nanotechnology formulations.
ON BEHALF OF THE BOARD
“Carolyn Myers”
Carolyn Myers
Chief Executive Officer and Director
Contacts:
Dr. Carolyn Myers, CEO and Director
1-800-344-9868
Alyssa Barry, Investor Relations
1-833-947-5227
investor@fendxtech.com
For more information, please visit https://fendxtech.com/ and the Company’s profile on SEDAR+ at www.sedarplus.ca.
Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; and products under development and any pathogen reduction benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “aims,” “potential,” “goal,” “objective,” “prospective,” and similar expressions, or that events or conditions “will,” “would,” “may,” “can,” “could” or “should” occur, or are those statements, which, by their nature, refer to future events. The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and involve several risks and uncertainties, including that the Offering may not close at all or on the terms announced; that the Company may use the proceeds of the Offering for purposes other than those disclosed in this news release; adverse market conditions; and other factors beyond the control of the Company. Consequently, there can be no assurances that such statements will prove to be accurate, and that actual results and future events could differ materially from those anticipated in such statements.
Important factors that could cause future results to differ materially from those anticipated in these forward-looking statements include: product candidates only being in formulation/reformulation stages; limited operating history; research and development activities; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other risk factors set forth in the Company’s public filings which are available on SEDAR+ at www.sedarplus.ca. Accordingly, the reader is urged to refer to the Company’s such filings for a more complete discussion of such risk factors and their potential effects. Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors should change.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/206095
The ticker symbol for FendX Technologies Inc. in the press release is FDXTF.
The services included in the agreement are PR/media, social media, and stakeholder relations.
The monthly fee for the agreement is $11,500.
The term of the agreement is for a period of twelve months ending on April 17, 2025.
The contact information for IR Labs Inc. is as follows: 2-21102 76 Avenue, Langley BC V2Y 4K7, attention: Alyssa Barry, email alyssa@irlabs.ca, telephone: 604-997-0965.
